Barth Syndrome is a rare genetic disorder that primarily affects males. It is estimated to occur in approximately 1 in every 200,000 to 400,000 live births worldwide. Although considered a rare condition, the prevalence may vary across different populations and regions.
Barth Syndrome is characterized by a range of symptoms including cardiomyopathy (weakening of the heart muscle), skeletal muscle weakness, growth delay, and low levels of neutrophils (a type of white blood cell). These symptoms can vary in severity and may present differently in affected individuals.
The disorder is caused by mutations in the TAZ gene, which is responsible for producing a protein involved in the structure and function of mitochondria. Mitochondria are essential for energy production within cells, and defects in the TAZ gene lead to impaired mitochondrial function.
Due to its rarity, Barth Syndrome often goes undiagnosed or misdiagnosed. It is important for healthcare professionals to be aware of the condition and consider it in individuals presenting with symptoms such as cardiomyopathy, muscle weakness, and growth delay.
While there is currently no cure for Barth Syndrome, management focuses on addressing specific symptoms and providing supportive care. This may include medications, physical therapy, and close monitoring of cardiac function.